Zhang Li-Juan, Li Shun-Ying, Fan Shao-Li, Nuerbiye Aobulikasimu, Zhao Jiu-Yang, Keremu Bahetiyaer, Yang Lu, Zhang Ke, Wang Hang-Yu, Wang Jin-Hui
Xinjiang Academy of Forestry, Key Laboratory of Forest Resources and Utilization in Xinjiang of National Forestry and Grassland Administration, Urumqi, Xinjiang 830000, China; Pharmaceutics College of Shihezi University/Key Laboratory of Xinjiang Plant Drug Resources Utilization Ministry of Education, Shihezi, Xinjiang, 832000, China.
Xinjiang Academy of Forestry, Key Laboratory of Forest Resources and Utilization in Xinjiang of National Forestry and Grassland Administration, Urumqi, Xinjiang 830000, China.
J Ethnopharmacol. 2025 Jul 24;351:120108. doi: 10.1016/j.jep.2025.120108. Epub 2025 Jun 7.
Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases worldwide, with an estimated global prevalence of 30 %. An imbalance in lipid metabolism leads to the accumulation of lipotoxic lipids, inducing cellular stress, activating the NLRP3 inflammasome, and triggering apoptotic cell death. This cascade stimulates inflammation, driving NAFLD progression. Morus nigra L. is the only black mulberry species native to China. In traditional Uygur medicine, its fruit is valued for its hepatoprotective and lipid-lowering effects.
The mechanism by which mulberry extract (ME) alleviates NAFLD remains unclear. This study aimed to investigate the hepatoprotective and anti-inflammatory effects of ME.
Network pharmacology was employed to predict the active components of ME and their potential target genes. Liver function markers (ALT, AST) and lipid profiles (TG, TC) were assessed using commercial assay kits. The therapeutic mechanism of ME against NAFLD was elucidated through an integrated approach combining transcriptomic and metabolomic analyses in a mouse NAFLD model.
UPLC-QTOF-MS analysis identified 131 active ingredients in ME. Network pharmacological analysis identified Akt1, Pparg, and Pparα as core targets. High-dose ME treatment markedly improved liver function, reducing ALT levels by 50 % and AST levels by 44 %, while also lowering hepatic TG by 22 % and TC by 15 %. Transcriptome analysis revealed that ME ameliorated NAFLD through AMPK/PPAR-γ/NF-κB axis. Metabolomic analysis demonstrated the involvement of unsaturated fatty acid and steroid hormone biosynthesis in NAFLD metabolism.
Our study demonstrates that ME alleviates NAFLD progression by regulating the AMPK/PPAR-γ/NF-κB signaling axis. However, these findings are based on preclinical animal studies, and further investigation is required to determine the clinical applicability of these effects in human patients.
非酒精性脂肪性肝病(NAFLD)是全球最常见的肝脏疾病之一,全球估计患病率为30%。脂质代谢失衡导致脂毒性脂质积累,引发细胞应激,激活NLRP3炎性小体,并触发细胞凋亡性死亡。这一系列反应刺激炎症,推动NAFLD进展。黑桑(Morus nigra L.)是中国唯一的本土黑桑品种。在传统维吾尔医学中,其果实因其保肝和降脂作用而受到重视。
桑椹提取物(ME)减轻NAFLD的机制尚不清楚。本研究旨在探讨ME的保肝和抗炎作用。
采用网络药理学预测ME的活性成分及其潜在靶基因。使用商业检测试剂盒评估肝功能指标(ALT、AST)和血脂谱(TG、TC)。通过在小鼠NAFLD模型中结合转录组学和代谢组学分析的综合方法,阐明ME抗NAFLD的治疗机制。
UPLC-QTOF-MS分析鉴定出ME中的131种活性成分。网络药理学分析确定Akt1、Pparg和Pparα为核心靶点。高剂量ME治疗显著改善肝功能,使ALT水平降低50%,AST水平降低44%,同时肝TG降低22%,TC降低15%。转录组分析表明,ME通过AMPK/PPAR-γ/NF-κB轴改善NAFLD。代谢组学分析表明,不饱和脂肪酸和类固醇激素生物合成参与NAFLD代谢。
我们的研究表明,ME通过调节AMPK/PPAR-γ/NF-κB信号轴减轻NAFLD进展。然而,这些发现基于临床前动物研究,需要进一步研究以确定这些作用在人类患者中的临床适用性。